 Grifols MCE: GRF, MCE: GRF.P, NASDAQ: GRFS, a leading global producer of plasma-derived medicines, will present the final and complete clinical, biomarker and neuroimaging results of its AMBAR Alzheimer Management by Albumin Replacement clinical trial at the Clinical Trials on Alzheimers Disease CTAD Conference in San Diego, Calif. USA. 